Skip to content

Study · Animal study (in vivo) · rat · 2000

4 results

[Carnosine stabilization of the normal erythrocyte membranes and in experimental diabetes].

Korobov VN, Maurisio RB, Mukalov IO, Stvolinskiĭ SL

Patologicheskaia fiziologiia i eksperimental'naia terapiia1 Apr 2000

PMID10846902 (opens in a new tab)PepBankPUB-10846902
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, carnosine prevented a decrease in red blood cell hemolytic stability.

    In plain wordsIn rats with diabetes, carnosine prevented a decrease in red blood cell resistance to rupture.

    Peptide
    L-carnosine
    Outcome
    IncreaseRed blood cell hemolytic stability
    Study

    ratn: not reported in source

    streptozotocin-induced diabetes
    Outcome group
    Blood counts and hematopoiesis · Whole body
    Studied dose
    50 mg/kg/day · oral · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    It was demonstrated on the model of streptozotocin-induced diabetes in rats that carnosine treatment (50 mg/kg/day during 7 days, per os) prevents a decrease in the hemolytic stability of red blood cells in diabetic animals.
  2. 02LabEx vivo tissueEfficacy outcome

    In healthy donor red blood cells, carnosine protected against acidic hemolysis.

    In plain wordsIn lab tests, carnosine protected healthy donor red blood cells against acid-induced rupture.

    Peptide
    L-carnosine
    Outcome
    DecreaseAcidic hemolysis
    Study

    humann: not reported in source

    healthy donors' red blood cells
    Outcome group
    Blood counts and hematopoiesis · Whole body
    Studied dose
    70-720 microMAs given in this study (human).

    Source sentences

    Summary
    Carnosine (70-720 microM) is shown to protect healthy donors' red blood cells from acidic hemolysis increasing population of stable red blood cells and postponing time to maximal rate of hemolysis.
  3. 03LabEx vivo tissueEfficacy outcome

    In healthy donor red blood cells, carnosine increased the population of stable cells.

    In plain wordsIn lab tests, carnosine increased the population of stable red blood cells from healthy donors.

    Peptide
    L-carnosine
    Outcome
    IncreaseStable red blood cell population
    Study

    humann: not reported in source

    healthy donors' red blood cells
    Outcome group
    Blood counts and hematopoiesis · Whole body
    Studied dose
    70-720 microMAs given in this study (human).

    Source sentences

    Summary
    Carnosine (70-720 microM) is shown to protect healthy donors' red blood cells from acidic hemolysis increasing population of stable red blood cells and postponing time to maximal rate of hemolysis.
  4. 04LabEx vivo tissueEfficacy outcome

    In healthy donor red blood cells, carnosine delayed the time to maximal hemolysis rate.

    In plain wordsIn lab tests, carnosine delayed the time to the fastest red blood cell rupture rate in healthy donor cells.

    Peptide
    L-carnosine
    Outcome
    IncreaseTime to maximal hemolysis rate
    Study

    humann: not reported in source

    healthy donors' red blood cells
    Outcome group
    Blood counts and hematopoiesis · Whole body
    Studied dose
    70-720 microMAs given in this study (human).

    Source sentences

    Summary
    Carnosine (70-720 microM) is shown to protect healthy donors' red blood cells from acidic hemolysis increasing population of stable red blood cells and postponing time to maximal rate of hemolysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.